IMR Press / FBL / Volume 10 / Issue 3 / DOI: 10.2741/1745

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with Frontiers in Bioscience.

Androgen metabolic genes in prostate cancer predisposition and progression
Show Less
1 Department of Biochemistry and Molecular Biology, Institute for Genetic Medicine, USC Keck School of Medicine, 2250 Alcazar Street, Los Angeles, CA 90089-9075, USA
2 Dame Roma Mitchell Cancer Research Laboratories, University of Adelaide & Hanson Institute, PO Box 14, Rundle Mall, Adelaide, SA 5000, Australia
3 University of Sydney, Medical Foundation Building (K25), 92 - 94 Parramatta Rd, Camperdown, Sydney, NSW 2042, Australia
Front. Biosci. (Landmark Ed) 2005, 10(3), 2892–2903;
Published: 1 September 2005

Significant evidence implicates androgens in prostate cancer etiology. We review recent data with regard to the association between several allelic variants of specific androgen-metabolic genes and the predisposition to prostate cancer. We also review the emerging evidence regarding the role of genetic variants of these genes as well as the androgen receptor in prostate cancer progression. Based on the prostate cancer paradigm, we propose that a multidisciplinary attack on the problem—involving biochemistry, genetics, pharmacogenetics, endocrinology and molecular epidemiology—may be important for the understanding and successful treatment of complex (in terms of etiology) human diseases.

Molecular Epidemiology
Androgen Metabolism
Single Nucleotide Polymorphism
Back to top